Setback for Boston after it recalls yet more stents
This article was originally published in Clinica
Executive Summary
In a development set to hurt its second quarter financial results, Boston Scientific has expanded the voluntarily recall of its drug-eluting Taxus stents and is also starting a recall of its Express2 bare metal stents.